**Observed Changes in Quality of Life Measures and Cerebrospinal Fluid Flow Parameters in Migraine Subjects Receiving Chiropractic Care**

H Charles Woodfield, B.S. Pharmacy, D.C.; Werner J. Becker, M.D.; D. Gordon Hasick, B.S., D.C.; M. Sarah Rose, Ph.D.


**Introduction**
This observational case series followed eleven migraine subjects investigating consistency and sustainability of previously observed changes in cerebrospinal and venous outflow parameters.

Using Phase Contrast MRI (PC-MRI) imaging, craniospinal flow changes were measured before-after subjects received a National Upper Cervical Chiropractic Association (NUCCA) atlas correction.

**Inclusion**
Subject's must be or have:
1. Male or female, 21 to 65 years of age.
2. Sign written informed consent.
4. Migraine with or without aura according to the International Classification of Headache Disorders (ICHD).
5. Ten to twenty-six headache days per month over the last 4 months.
6. Be suitable candidates for therapeutic intervention as assessed by NUCCA investigator.

**Exclusion**
Presence of:
1. Any medical or psychiatric condition that would interfere with study completion.
2. More than twenty-six headache days a month.
3. Acute medication overuse.
4. Pregnancy or lactation.
5. Severe cervical spine degeneration.
6. Claustrophobia.
7. Current participation in a research study or within the past thirty days.
8. Chiropractic care outside of the study protocol is prohibited.
9. History of significant head or neck trauma (as judged by the investigator) within one year prior to study entry.

**Results**
- Eighteen (18) subjects screened.
- Eleven subjects studied; 8 female, 3 males.
- Average age: 41 years (range 20 - 61).
- Ten (10) subjects presented migraine without aura.
- Six (6) subjects reported chronic migraine.
- Migraine duration range: 2 to 35 years.
- Mean: 23 years.
- Subjects remained on medications. Use decreased.
- Total measured Entrance Skin Radiation Exposure of before-after correction radiographs was 352 millirads (3.52 millisievers).
- Ten subjects self-reported tolerable mild neck pain occurring for more than 24 hours after intervention. Pain had little impact on daily activities.

**Conclusions**
- Consistency of magnitude & direction of improvement across HRQoL measures indicates improvement in headache head.
- One pilot study limitation is the absence of a control group.
- Many pharmaceutical studies have shown substantial placebo effect.
- Results indicate a randomized controlled trial is warranted.
- Sample size estimates can be determined for future study.
- Literature reports a secondary venous outflow pattern exists for many migraine patients.
- Significance of increase in compliance of subjects with secondary drainage remains unknown.

**Subject Conveyance**
- Fit inclusion criteria
- Sign consent
- Neurologist screen
- Baseline MIDAS
- 90-day HA Diary
- NUCCA Screen

**Outcomes Collection**
End of Study
- Neurologist exit interview
- MIDAS
- Collect HA Diary

**Subject Inclusion**
- NUCCA protocol followed for 8 weeks
- VAS each visit
- Check HA Diary
- Check adverse reactions 7 day after intervention

**Fig 1:** Shows a ‘scout’ lateral MRI image. Note the transverse line. The velocity encoded image obtained from this region is Fig 2.

**Fig 2:** Shows a cardiac gated Phase Contrast Velocity Encoded Image of the area noted in Fig 1.

**Fig 3:** Demonstrates the proprietary translation of MRI data; Intracranial Compliance Index (ICCI) is determined using this data.

**Results - Intracranial Compliance Index**

<table>
<thead>
<tr>
<th>Jugular Venous Drainage</th>
<th>Secondary Venous Drainage</th>
</tr>
</thead>
<tbody>
<tr>
<td>n = 7</td>
<td>n = 4</td>
</tr>
<tr>
<td>5.83 (4.52, 6.89)</td>
<td>7.71 (6.18, 9.14)</td>
</tr>
<tr>
<td>5.77 (4.52, 6.89)</td>
<td>6.79 (5.26, 8.23)</td>
</tr>
<tr>
<td>5.74 (4.52, 6.89)</td>
<td>10.07 (8.54, 11.59)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Baseline</th>
<th>4 week Mean (SD)</th>
<th>8 week Mean (SD)</th>
<th>Difference Baseline to 4 wks. Mean (95% CI)</th>
<th>p-value</th>
<th>Difference Baseline to 8 wks. Mean (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache Day</td>
<td>14.5 (7.4)</td>
<td>11.4 (7.4)</td>
<td>8.7 (6.1, 9.9)</td>
<td>p = 0.031</td>
<td>5.7 (2.0, 9.4)</td>
<td>p = 0.001</td>
</tr>
<tr>
<td>Headache Intensity</td>
<td>2.8 (1.2)</td>
<td>2.6 (1.2)</td>
<td>2.1 (1.0, 3.2)</td>
<td>p = 0.009</td>
<td>0.69 (0.42, 1.2)</td>
<td>p = 0.001</td>
</tr>
</tbody>
</table>

**Results - HRQoL Measures**

<table>
<thead>
<tr>
<th>Baseline Mean (SD)</th>
<th>12 week Mean (SD)</th>
<th>Difference Baseline to 12 week Mean (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIDAS</td>
<td>42.7 (27.7)</td>
<td>32.3 (23.8)</td>
<td>10.4 (5.9, 13.8)</td>
</tr>
</tbody>
</table>

**References**

**Acknowledgments**
1. Alpinix Diagnostics, Inc, Miami FL. Dr. Noam Alperin.
2. Britannia Clinic, Calgary, AB. Kathy Waters, Study Coordinator, Dr. Ausmus.
3. Elliot Fong Wallace, Calgary, AB. Sue Curtis, MRI Technologist, Dr. James Scott.
4. CHAMP, Calgary, AB. Brenda Kelly-Besler, RN, Research Coordinator.